Kanghuai Zhang

Kanghuai Zhang


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
JXJiao Xie
Jiao Xie
JRJason A. Roberts
Jason A. Roberts
JLJeffrey Lipman
Jeffrey Lipman
YCYan Cai
Yan Cai
HWHaitao Wang
Haitao Wang
KZKanghuai Zhang
Kanghuai Zhang

27 October 2018 in Journal of Clinical Pharmacy and Therapeutics
Verified
Journal Article
Closed access
PDF file
YCYan Cai
Yan Cai
LZLe Zhou
Le Zhou
HWHuqing Wang
Huqing Wang
LZLi Zhang
Li Zhang
JWJinqiu Wang
Jinqiu Wang
KZKanghuai Zhang
Kanghuai Zhang

10 June 2021 in Journal of Clinical Pharmacy and Therapeutics
Verified
Journal Article
Closed access
PDF file
YCYan Cai
Yan Cai
MZMinggang Zhang
Minggang Zhang
YWYan Wang
Yan Wang
NWNa Wang
Na Wang
LZLi Zhang
Li Zhang
KZKanghuai Zhang
Kanghuai Zhang

1 January 2021 in American Journal of Infection Control
Verified
Journal Article
Closed access
YWYan Wang
Yan Wang
HZHan Zhong
Han Zhong
XHXinyan Han
Xinyan Han
NWNa Wang
Na Wang
YCYan Cai
Yan Cai
KZKanghuai Zhang
Kanghuai Zhang

20 August 2025 in Frontiers in Public Health
Verified
Journal Article
Open access
PDF file
QSQian Shen
Qian Shen
LKLimin Kang
Limin Kang
DYDan Ye
Dan Ye
YLYoujia Li
Youjia Li
KZKanghuai Zhang
Kanghuai Zhang
Background: Since 2019, the Chinese government has been fully implementing the National Centralized Drug Procurement (NCDP) policy, with the core objective of reducing drug costs and alleviating the medical burden on patients. As the practitioners of this policy, healthcare professionals (HCPs) play a crucial role in its implementation. Therefore, it is necessary to evaluate their knowledge, attitudes, and practices (KAP) regarding the implementation of the (NCDP) policy and the factors influencing these aspects.Methods: We conducted a cross-sectional online survey on HCPs from public hospitals in Shaanxi Province from 2022 August to September. A structured self-administered questionnaire was used to collect data on demographics, knowledge of NCDP, attitude toward NCDP policy, and practice of policy implementation. KAP adequacy was dichotomized at the 70% cut-off (Knowledge: adequate vs. inadequate, Attitude: positive vs. negative; Practice: good vs. poor). All the variables were descriptively analyzed, and multivariate logistics regression analysis was used to explore the factors associated with KAP level.Results: A total of 1,257 valid responses were received. Of these, 58.4% demonstrated adequate knowledge, 63.2% held positive attitudes, and 35.2% exhibited good practices. Significant occupational disparities emerged, with pharmacists outperforming physicians across all KAP domains (p < 0.01). Multivariate logistic regression analysis showed that professional title, being a pharmacist, and attending the training were independently associated with adequate knowledge. Positive attitudes were significantly associated with 11–20 years of working experience, having a bachelor’s degree, being a pharmacist, and attending training. Proactive practice was associated with longer working years, being a pharmacist, and training attendance. The main concerns of HCPs regarding the NCDP policy were guaranteeing medicine quality (93.2%), strengthening clinical outcomes research (80.0%), and strengthening monitoring of adverse reactions (79.6%).Conclusion: Our study found that HCPs in Shaanxi Province possessed a moderate level of knowledge and generally positive attitudes toward the NCDP policy, yet demonstrate room for enhanced practice. Pharmacists play a pivotal role in policy implementation. To strengthen HCPs’ policy endorsement and ensure faithful implementation, targeted training on therapeutic effectiveness and safety evaluation is essential, as it can alleviate clinical concerns and bridge the gap from evidence to actionable competence. Future research should concentrate on generating high-quality clinical evidence, analyzing long-term policy impacts, identifying implementation barriers, and designing educational interventions to bolster HCPs’ knowledge and positive attitudes regarding the NCDP policy.

26 November 2024 in Discover Oncology
Verified
Journal Article
Open access
PDF file
FHFei He
Fei He
YSYancai Sun
Yancai Sun
WZWenzhou Zhang
Wenzhou Zhang
QWQiongshi Wu
Qiongshi Wu
DXDong-Hang Xu
Dong-Hang Xu
GLguohui Li
guohui Li
Objective This study aimed to assess the safety and efficacy of generic nab-paclitaxel in the Chinese population in a real-world setting. Methods This prospective, multicenter, observational study enrolled patients with malignancies who received any generic nab-paclitaxel-based regimens in China. The primary endpoint was safety, and secondary endpoint was objective response rate (ORR). Logistic regression was used to explore risk factors for adverse events (AEs) of special interest (AESIs). Results Between September 2019 and April 2023, 1168 patients were enrolled and evaluated for safety, and 602 were assessed for tumor response. Of 1168 patients, 169 (14.5%) received generic nab-paclitaxel monotherapy, and 999 (85.5%) received generic nab-paclitaxel-based combination therapy. Grade 3–4 AEs occurred in 19.3% (225/1168) patients, most commonly including neutrophil count decreased (7.6%), anemia (5.8%), and white blood cell decreased (5.7%). In subgroup analysis, peripheral sensory neuropathy was observed frequently in breast cancer (45.6%). Multivariate analysis showed that patients receiving combination therapy and ≥ 4 treatment cycles (OR, 1.925; 95% CI 1.363–2.719; p < 0.001) were more susceptible to the AESIs. Conclusions This study demonstrates a promising safety and efficacy of generic nab-paclitaxel-based regimens for Chinese patients with malignancies in a real-world setting, providing valuable insights for clinical decision-making. Clinical Trials.gov NCT04060290